Iron Substitution in Blood Donors (ISUB)
|ClinicalTrials.gov Identifier: NCT01519830|
Recruitment Status : Completed
First Posted : January 27, 2012
Last Update Posted : February 28, 2013
Depletion of iron stores is frequently observed in regular blood donors, but effects of iron deficiency on general health is not well studied. Recent studies in women suffering of fatigue suggest iron deficiency without concomitant anemia as a common cause of these complaints. Provided the same is true in healthy subjects, substitution of intravenous iron might result in an improvement of general well being in iron depleted blood donors.
Healthy regular blood donors will be screened for low storage iron. Qualifying subjects will be invited to participate in a randomized, placebo-controlled trial with substitution of intravenous iron or placebo (saline solution). Differences in subjectively felt fatigue and other factors of general health and well being will be assessed. If an improvement of such factors can be shown after iron replacement, relevant concerns about artificially lowering iron stores by repeated phlebotomies will arise and changes of monitoring and substitution policies in blood banking might have to be discussed.
|Condition or disease||Intervention/treatment||Phase|
|Fatigue||Drug: Iron carboxymaltose (Ferinject) Drug: Placebo||Phase 4|
Chronic iron deficiency causes anemia with impairment of physical and mental capacity. Since iron plays an essential role in many enzymes apart from oxygen carriage, iron deficiency was proposed as an independent factor impairing wellbeing also without anemia. Symptoms like fatigue, asthenia, physical weakness, mental impairment and many others have been associated with iron deficiency. Recent clinical trials with iron substitution in iron deficient women suffering of general fatigue support this hypothesis, but data are still conflicting and debated.
Low body iron stores are frequently observed in blood donors. Repeated phlebotomies may induce or aggravate severe iron deficiency. Astonishingly, little is known about the long term effects of reduced iron stores on general health of regular blood donors. Serious health impairment cannot be excluded conclusively. Since many symptoms associated with iron deficiency are subtle, they might be missed by otherwise healthy subjects.
Blood donors with borderline or decreased iron stores (i.e. serum ferritin below 50 microg/l) will be invited to participate in a randomized, placebo-controlled intervention study comparing intravenous iron carboxymaltose and a physiological saline solution (placebo). Subjectively felt fatigue, measured on a numeric rating scale from 1 to 10 as the major end point will be assessed before and six months after application of the study drug. As additional factors, various aspects of general wellbeing will be assessed using four psychometric questionnaires. Statistical analysis will compare the results before and after application of the study drug and the results of the two study arms.
- Assessment of severity of iron deficiency in a large group of blood donors.
- Demonstration of an improvement of fatigue after substitution of iron compared with placebo in iron deficient blood donors
- Detection of improved general wellbeing in otherwise healthy blood donors after substitution of intravenous iron
- Assessment of tolerability of intravenous iron in healthy blood donors
Randomized, placebo controlled interventional trial comparing the effect of intravenous iron or placebo on fatigue and various other factors of general wellbeing. Endpoints assessed on a numeric rating scale from 1 to 10 and four psychometric questionnaires.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||405 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Significance of Iron Deficiency in Transfusion Medicine: Effects of Iron Substitution on Fatigue Und General Well Being in Healthy Blood Donors|
|Study Start Date :||January 2012|
|Primary Completion Date :||January 2013|
|Study Completion Date :||January 2013|
Iron Carboxymaltose (Ferinject)
Drug: Iron carboxymaltose (Ferinject)
Placebo Comparator: Placebo
0.9% NaCl solution
0.9% NaCl solution
- Difference of fatigue on a 10 point numeric scale after intravenous substitution of iron or placebo [ Time Frame: 6 weeks ]measured by questionnaire
- Change of fatigue after intravenous substitution of iron [ Time Frame: 6 weeks ]measured by questionnaire
- Improvement of general wellbeing [ Time Frame: 6 weeks ]measured by questionnaire
- Number of patients with adverse events of different grades [ Time Frame: 6 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01519830
|Department of Hematology, Bern University Hospital|
|Bern, Switzerland, CH-3010|
|Study Chair:||Peter Keller, MD||Department of Hematology, Bern University Hospital, Switzerland|
|Study Chair:||Bernhard Lämmle, MD, Prof.||Department of Hematology, Bern University Hospital, Switzerland|
|Study Chair:||Stefano Fontana, MD||Blutspendedienst SRK Bern AG, Bern, Switzerland|
|Study Chair:||Peter Jüni, MD, Prof.||Institut für Sozial- und Präventivmedizin, Universität Bern, Switzerland|
|Study Chair:||Roland von Känel, MD, Prof.||Kompetenzbereich für Psychosomatische Medizin, University Hospital Bern|